Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
Amirian and Levy have recently collected the knowledge on remdesivir and its nucleoside analog [1]. This overview can be interesting
Tag: remdesivir
First copies of Gilead’s SBECD-enabled remdesivir to start selling in Bangladesh
According to Hindustan Times, Bangladesh’s Beximco Pharmaceuticals Ltd. has become the world’s first company to start selling the generic version
Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand
Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
Japan approved the Gilead Sciences antiviral drug remdesivir Thursday for treatment of severe COVID-19 patients, under an exceptional approval pathway
Gilead outlines plans to distribute COVID-19 drug worldwide
Gilead on Tuesday said it is negotiating with overseas drug manufacturers to license its SBECD-enabled coronavirus treatment remdesivir in an effort
Az amerikai gyógyszerhatóság (FDA) engedélyezte a ciklodextrinnel formulázott remdesivir használatát COVID-19 kezelésére
A Gilead Sciences, Inc. amerikai gyógyszercég tegnap bejelentette, hogy a U.S. Food and Drug Administration (FDA, amerikai gyógyszerhatóság) úgynevezett “emergency
SBECD-enabled Remdesivir Receives FDA’s Emergency Use Authorization for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for
Gilead’s Remdesivir meets main goal of trial in COVID-19 patients
Gilead Sciences today announced that preliminary results of a coronavirus drug trial showed at least 50% of patients treated with
Japan to approve remdesivir for coronavirus patients in May
Prime Minister Shinzo Abe said Monday that Japan will soon approve the SBECD-eanbled anti-viral drug remdesivir for the treatment of
Gilead’s remdesivir significantly reduces COVID-19 symptoms in rhesus monkeys in NIH trial
A recently published study from the National Institutes of Health reports on the efficacy of Gilead’s promising antiviral therapy remdesivir